(Arg)9 TFA (Synonyms: Nona-L-arginine TFA; Peptide R9 TFA)

Cat. No.: HY-P0133A: FAQs
Data Sheet SDS Handling Instructions

Molarity Calculator

(Arg)9 (Nona-L-arginine) TFA is a cell-penetrating peptide (CPP) made up of 9 arginine residues. (Arg)9 TFA has neuroprotective property, exhibits neuroprotective activity with an IC₅₀ of 0.78 μM in the glutamic acid model.

For research use only. We do not sell to patients.

(Arg)9 TFA Chemical Structure

CAS No. : 2283335-13-5

Size		Stock
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of (Arg)9 TFA:

Other Forms of (Arg)9 TFA:

(Arg)9 acetate In-stock
(Arg)9 Get quote

1 Publications Citing Use of MCE (Arg)9 TFA

•In Vitro Cell Dev Biol-Pl. 06 January 2022.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

IC50: 0.78 μM (neuroprotection)^[1].

In Vitro

(Arg)9 (Nona-L-arginine; 5-10 μM) TFA provides significant neuroprotection in a dose–response manner following glutamic acid exposure (IC₅₀=0.78 μM). Following kainic acid exposure, (Arg)9 TFA is neuroprotective, but less effective than in the glutamic acid model (IC₅₀=0.81 μM). (Arg)9 TFA also shows neuroprotection following in vitro ischemia (IC₅₀=6 μM)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

(Arg)9 (Nona-L-arginine; 1 μM/kg (600 μL); i.v.; once, for 30min; male Sprague–Dawley ratspermanent middle cerebral artery stroke model) TFA shows neuroprotective effects and reduces infarct volume^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague–Dawley rats (270 to 320 g) permanent middle cerebral artery stroke model^[2]
Dosage:	1 μM/kg (600 μL)
Administration:	Intravenous injection; once, over 5 minutes
Result:	Reduced significantiy 20% in infarct volume.

Molecular Weight

1423.69 (free acid)

Formula

C₅₄H₁₁₀N₃₆O₁₀.xC₂HF₃O₂

CAS No.

2283335-13-5

Appearance

Solid

Color

White to off-white

Sequence

Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg

Sequence Shortening

RRRRRRRRR

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

H₂O

Peptide Solubility and Storage Guidelines:

1. Calculate the length of the peptide.

2. Calculate the overall charge of the entire peptide according to the following table:

	Contents	Assign value
Acidic amino acid	Asp (D), Glu (E), and the C-terminal -COOH.	-1
Basic amino acid	Arg (R), Lys (K), His (H), and the N-terminal -NH₂	+1
Neutral amino acid	Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q)	0

3. Recommended solution:

Overall charge of peptide	Details
Negative (<0)	1. Try to dissolve the peptide in water first. 2. If water fails, add NH₄OH (<50 μL). 3. If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (>0)	1. Try to dissolve the peptide in water first. 2. If water fails, try dissolving the peptide in a 10%-30% acetic acid solution. 3. If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0)	1. Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first. 2. For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.

Purity & Documentation

Data Sheet (270 KB) SDS (252 KB) Handling Instructions (2659 KB)

References

[1]. Meloni BP, et, al. The neuroprotective efficacy of cell-penetrating peptides TAT, penetratin, Arg-9, and Pep-1 in glutamic acid, kainic acid, and in vitro ischemia injury models using primary cortical neuronal cultures. Cell Mol Neurobiol. 2014 Mar;34(2):173-81. [Content Brief]

[2]. Meloni BP, et, al. Poly-arginine and arginine-rich peptides are neuroprotective in stroke models. J Cereb Blood Flow Metab. 2015 Jun;35(6):993-1004. [Content Brief]

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

(Arg)92283335-13-5Nona-L-argininePeptide R9Peptide R 9Peptide R-9Otherscell-penetrating peptideneuroprotective propertyarginineinfarct volumeInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks